Nina Greilert

Publikationer
Populärvetenskap och samverkan

Artiklar

Article: IMMUNITY INFLAMMATION AND DISEASE. 2022;10(4):e595

Long-term SARS-CoV-2-specific and cross-reactive cellular immune responses correlate with humoral responses, disease severity, and symptomatology.

Laurén I; Havervall S; Ng H; Lord M; Pettke A; Greilert-Norin N; Gabrielsson L; Chourlia A; Amoêdo-Leite C; Josyula VS; Eltahir M; Kerzeli I; Falk AJ; Hober J; Christ W; Wiberg A; Hedhammar M; Tegel H; Burman J; Xu F; Pin E; Månberg A; Klingström J; Christoffersson G; Hober S; Nilsson P; Philipson M; Dönnes P; Lindsay R; Thålin C; Mangsbo S
Article: VACCINES. 2022;10(3):359

Duration of SARS-CoV-2 Immune Responses Up to Six Months Following Homologous or Heterologous Primary Immunization with ChAdOx1 nCoV-19 and BNT162b2 mRNA Vaccines.

Marking U; Havervall S; Greilert-Norin N; Ng H; Blom K; Nilsson P; Phillipson M; Hober S; Nilsson C; Mangsbo S; Christ W; Klingström J; Gordon M; Åberg M; Thålin C
Article: CLINICAL & TRANSLATIONAL IMMUNOLOGY. 2022;11(4):e1388

Impact of SARS-CoV-2 infection on vaccine-induced immune responses over time.

Havervall S; Marking U; Greilert-Norin N; Gordon M; Ng H; Christ W; Phillipson M; Nilsson P; Hober S; Blom K; Klingström J; Mangsbo S; Åberg M; Thålin C
Article: PLOS ONE. 2022;17(1):e0262169

SARS-CoV-2 induces a durable and antigen specific humoral immunity after asymptomatic to mild COVID-19 infection.

Havervall S; Jernbom Falk A; Klingström J; Ng H; Greilert-Norin N; Gabrielsson L; Salomonsson A-C; Isaksson E; Rudberg A-S; Hellström C; Andersson E; Olofsson J; Skoglund L; Yousef J; Pin E; Christ W; Olausson M; Hedhammar M; Tegel H; Mangsbo S; Phillipson M; Månberg A; Hober S; Nilsson P; Thålin C
Article: JOURNAL OF INTERNAL MEDICINE. 2022;291(1):72-80

Robust humoral and cellular immune responses and low risk for reinfection at least 8 months following asymptomatic to mild COVID-19.

Havervall S; Ng H; Jernbom Falk A; Greilert-Norin N; Månberg A; Marking U; Laurén I; Gabrielsson L; Salomonsson A-C; Aguilera K; Kihlgren M; Månsson M; Rosell A; Hellström C; Andersson E; Olofsson J; Skoglund L; Yousef J; Pin E; Lord M; Åberg M; Hedhammar M; Tegel H; Dönnes P; Phillipson M; Nilsson P; Klingström J; Mangsbo S; Hober S; Thålin C
Article: STROKE. 2021;52(10):3082-3087

Effects of Fluoxetine on Outcomes at 12 Months After Acute Stroke: Results From EFFECTS, a Randomized Controlled Trial.

Lundström E; Isaksson E; Greilert Norin N; Näsman P; Wester P; Mårtensson B; Norrving B; Wallén H; Borg J; Hankey GJ; Hackett ML; Mead GE; Dennis MS; Sunnerhagen KS
Article: EBIOMEDICINE. 2021;70:103523

Antibody responses after a single dose of ChAdOx1 nCoV-19 vaccine in healthcare workers previously infected with SARS-CoV-2.

Havervall S; Marking U; Greilert-Norin N; Ng H; Gordon M; Salomonsson A-C; Hellström C; Pin E; Blom K; Mangsbo S; Phillipson M; Klingström J; Hober S; Nilsson P; Åberg M; Thålin C

Alla övriga publikationer

Letter: LANCET INFECTIOUS DISEASES. 2024;24(2):e80-e81

Humoral immune responses to the monovalent XBB.1.5-adapted BNT162b2 mRNA booster in Sweden.

Marking U; Bladh O; Aguilera K; Yang Y; Greilert Norin N; Blom K; Hober S; Klingström J; Havervall S; Åberg M; Sheward DJ; Thålin C
Letter: NEW ENGLAND JOURNAL OF MEDICINE. 2023;389(17):1626-1628

Mucosal and Serum Antibodies 3 Weeks after Symptomatic BA.2.86 Infection.

Bladh O; Greilert-Norin N; Havervall S; Marking U; Aguilera K; Alm JJ; Blom K; Åberg M; Klingström J; Thålin C
Letter: THE LANCET REGIONAL HEALTH - EUROPE. 2023;33:100725

Point prevalence of SARS-CoV-2 infection among healthcare workers in March and June 2023 in Sweden.

Blom K; Bladh O; Havervall S; Marking U; Greilert Norin N; Alm JJ; Klingström J; Thålin C
Letter: LANCET INFECTIOUS DISEASES. 2023;23(8):e272-e273

Mucosal IgA protects against BQ.1 and BQ.1.1 infection.

Marking U; Bladh O; Havervall S; Greilert-Norin N; Gordon M; Alm JJ; Blom K; Åberg M; Klingström J; Thålin C
Letter: LANCET INFECTIOUS DISEASES. 2023;23(2):150-152

7-month duration of SARS-CoV-2 mucosal immunoglobulin-A responses and protection.

Marking U; Bladh O; Havervall S; Svensson J; Greilert-Norin N; Aguilera K; Kihlgren M; Salomonsson A-C; Månsson M; Gallini R; Kriegholm C; Bacchus P; Hober S; Gordon M; Blom K; Smed-Sörensen A; Åberg M; Klingström J; Thålin C
Letter: NEW ENGLAND JOURNAL OF MEDICINE. 2022;387(14):1333-1336

Anti-Spike Mucosal IgA Protection against SARS-CoV-2 Omicron Infection.

Havervall S; Marking U; Svensson J; Greilert-Norin N; Bacchus P; Nilsson P; Hober S; Gordon M; Blom K; Klingström J; Åberg M; Smed-Sörensen A; Thålin C
Preprint: MEDRXIV. 2022

High prevalence of olfactory disorders 18 months after contracting COVID-19: a case-control study

Frasnelli J; Tognetti A; Thunell E; Winter A; Olsson M; Greilert N; Olofsson J; Havervall S; Thålin C; Lundström J

Artiklar

Alla övriga publikationer

Nyheter från KI

Kalenderhändelser från KI